SCIENTIFIC BACKGROUND

B3GALT6, B4GALT7, SLC39A13

EDS caused by B4GALT7 deficiency (spEDS-B4GALT7) and B3GALT6 deficiency (spEDS-B3GALT6)

Characteristic clinical symptoms of spondylodysplastic Ehlers-Danlos syndromes (spEDS), previously referred to as progeroid subtypes, include an aged appearance, developmental delay, short stature, craniofacial dysproportion, generalized osteopenia, impaired wound healing, hypermobile joints, muscle hypotonia, and loose but elastic skin.

Molecular causes are homozygous or combined heterozygous variants in the B4GALT7 and B3GALT6 genes. Both genes encode a UDP-galactose: O-beta-D-xylosylprotein 4-beta-D-galactosyltransferase and beta-1,3-galactosyltransferase 6, respectively. Galactosyltransferase I deficiency results in deficiency of small proteodermatan sulfates within glycosaminoglycan biosynthesis. B3GALT6 variants were originally identified in spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL1).

 

EDS caused by SLC39A13 variants (spEDS-SLC39A13)

Patients with the very rare EDS type formerly known as spondylocheirodysplastic EDS (SCD-EDS) have thin, translucent, hyperextensible, velvety, fragile skin with atrophic scars; slender, tapered fingers; and joint contractures. Additional characteristic clinical symptoms include skeletal dysplasia (spondylo) with moderate short stature, and characteristic hand abnormalities with wrinkled palms and atrophy of the muscles at the base of the thumb and palm of the hand (cheiro).

spEDS-SLC39A13 is caused by variants in the zinc transporter gene SLC39A13. To date, only three homozygous loss-of-function variants in the SLC39A13 gene have been described in nine patients from three families. Patients with spEDS-SLC39A13 have a urinary LP/HP ratio of approximately 1.0, which is a value between controls and patients with kyphoscoliotic EDS (kEDS-PLOD1).

 

References

Van Damme et al. 2018, Hum Mol Genet 27:3475 / Brady et al. 2017, Am J Med Genet C 175:70 / Ritelli et al. 2017, Orphanet J Rare Dis 12:153 / Vorster et al. 2014, Clin Genet 87:492) / Guo et al. 2013, Am J Med Genet A 161:2519 / Nakajima et al. 2013, Am J Hum Genet 92:927 / Giunta et al 2008, Am J Hum Genet 82:1290 / Fukada et al. 2008, PLoS One 3:e3642 / Faiyaz-Ul-Haque et al. 2004, Am J Med Genet 128A:39 / Okajima et al. 1999, J Biol Chem 274:28841

GENES

B3GALT6, B4GALT7, SLC39A13
How to order

LATEST ARTICLES

Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant...

Read more

Colorectal cancer remains a significant health concern globally. While genetic factors play a crucial role in its development, identifying the exact ...

Read more

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more